Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.
Pharmacological agents, such as histamine H(2) receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK(2) receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.
Aihara
Takeshi
T
Department of Applied Pharmacology, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto 607-8414, Japan.
Nakamura
Eiji
E
Amagase
Kikuko
K
Tomita
Kazuyoshi
K
Fujishita
Teruaki
T
Furutani
Kazuharu
K
Okabe
Susumu
S
D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D005744:Gastric Acid / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D051379:Mice; D018345:Mice, Knockout / Q000235:genetics; D010295:Parietal Cells, Gastric / Q000502:physiology; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000503:physiopathology
D000897:Anti-Ulcer Agents